Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma

•PD-L1 22C3 is used to select head and neck patients for pembrolizumab treatment.•There is a clinical demand for PD-L1 immunohistochemistry laboratory developed tests.•Concordance between the laboratory developed test and pharmDx assay is almost perfect.•Interobserver agreement is substantial and co...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oral oncology 2022-11, Vol.134, p.106086-106086, Article 106086
Hauptverfasser:	Hempenius, Maaike Anna, Bisheshar, Sangeeta Kareshma, Slagter-Menkema, Lorian, van der Kamp, Martine Froukje, Halmos, Gyorgy Bela, Doff, Jan Johannes, Willems, Stefan Martin, van der Vegt, Bert
Format:	Artikel
Sprache:	eng
Schlagworte:	22C3 antibody Assay comparison Head and neck squamous cell carcinoma Immunohistochemistry Immunotherapy Pembrolizumab Programmed cell death-ligand 1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!